Literature DB >> 18940266

Prokinetics and fundic relaxants in upper functional GI disorders.

Jan Tack1.   

Abstract

Gastrointestinal prokinetics are a heterogeneous class of drugs that stimulate smooth muscle contractions to enhance gastric emptying and intestinal transit. Recently studied prokinetics include antidopaminergic agents (itopride), serotonergic agents (tegaserod and others), and motilin receptor agonists and ghrelin receptor agonists (mitemcinal, TZP101). It has been difficult to establish symptomatic benefit with prokinetic drugs in gastroparesis and functional dyspepsia, because of pathophysiological heterogeneity of the patient populations, a lack of well-accepted endpoints, and inconsistent relationships between changes in motor function and symptomatic outcome. Fundic relaxant drugs are a recent different approach to treatment of gastric motility disorders. Recently studied drugs include drugs under investigation including nitrates, serotonin reuptake blockers, 5-HT(1A) receptor agonists (buspirone and R137696), and muscarinc M1/M2 receptor antagonists (acotiamide or Z-338).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940266     DOI: 10.1016/j.coph.2008.09.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  25 in total

1.  Gastroparesis: current concepts and management.

Authors:  Tatsuhiro Masaoka; Jan Tack
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

2.  Functional abdominal pain and irritable bowel syndrome in children and adolescents.

Authors:  Eric Chiou; Samuel Nurko
Journal:  Therapy       Date:  2011-05-01

Review 3.  Management of functional abdominal pain and irritable bowel syndrome in children and adolescents.

Authors:  Eric Chiou; Samuel Nurko
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 3.869

Review 4.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 5.  Diabetes and the Esophagus.

Authors:  Roberto Monreal-Robles; José M Remes-Troche
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

6.  Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility.

Authors:  Zoltán S Zádori; Ágnes Fehér; Viktória E Tóth; Mahmoud Al-Khrasani; László Köles; Szabina Sipos; Fabio Del Bello; Maria Pigini; Klára Gyires
Journal:  Dig Dis Sci       Date:  2016-02-10       Impact factor: 3.199

7.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

8.  Dyspepsia in the community: value of a community-based mailed survey to identify potential participants for a randomized clinical trial.

Authors:  Linda M Herrick; Giles Richard Locke; Cathy D Schleck; Alan R Zinsmeister; Vickie Treder; Nicholas J Talley
Journal:  Scand J Gastroenterol       Date:  2015-03-11       Impact factor: 2.423

9.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

10.  The prokinetic face of ghrelin.

Authors:  Hanaa S Sallam; Jiande D Z Chen
Journal:  Int J Pept       Date:  2010-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.